Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management

por Dejager, Sylvie, Schweizer, Anja
Publicado 2011

Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment

por Schweizer, Anja, Dejager, Sylvie
Publicado 2013

Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan

por Schweizer, Anja, Halimi, Serge, Dejager, Sylvie
Publicado 2013

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

por Dejager, Sylvie, Schweizer, Anja, Foley, James E
Publicado 2012

Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin

por Schweizer, Anja, Dejager, Sylvie, Foley, James E.
Publicado 2012

Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes: Is this of concern?

por Monnier, Louis, Colette, Claude, Dejager, Sylvie, Owens, David
Publicado 2013

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

por Schweizer, Anja, Dejager, Sylvie, Foley, James E, Kothny, Wolfgang
Publicado 2011

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

por Evans, Marc, Dejager, Sylvie, Schweizer, Anja, Foley, James E.
Publicado 2015

Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study

por Penfornis, Alfred, Fiquet, Béatrice, Blicklé, Jean Frédéric, Dejager, Sylvie
Publicado 2015

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet

por Halimi, Serge, Schweizer, Anja, Minic, Biljana, Foley, James, Dejager, Sylvie
Publicado 2008

Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study

por Halimi, Serge, Levy, Marc, Huet, Dominique, Quéré, Stéphane, Dejager, Sylvie
Publicado 2013

Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French healt...

por Detournay, Bruno, Halimi, Serge, Robert, Julien, Deschaseaux, Céline, Dejager, Sylvie
Publicado 2015

How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study

por Penfornis, Alfred, Blicklé, Jean Frédéric, Fiquet, Béatrice, Quéré, Stéphane, Dejager, Sylvie
Publicado 2014

Patient perceptions and understanding of treatment instructions for ovarian stimulation during infertility treatment

por Barrière, Paul, Avril, Catherine, Benmahmoud-Zoubir, Amel, Bénard, Nathalie, Dejager, Sylvie
Publicado 2019

Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database

por Emery, Corinne, Torreton, Elodie, Dejager, Sylvie, Levy-Bachelot, Laurie, Bineau, Sébastien, Detournay, Bruno
Publicado 2020

Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study

por Simon, Dominique, Detournay, Bruno, Eschwege, Evelyne, Bouée, Stephane, Bringer, Jacques, Attali, Claude, Dejager, Sylvie
Publicado 2014

Physical activity in patients with type 2 diabetes and hypertension – insights into motivations and barriers from the MOBILE study

por Duclos, Martine, Dejager, Sylvie, Postel-Vinay, Nicolas, di Nicola, Sylvie, Quéré, Stéphane, Fiquet, Béatrice
Publicado 2015

Breaking Barriers to Effective Type 2 Diabetes Management: Findings from the use of the OPTIMA© Questionnaire in Clinical Practice

por Grimaldi, André, Penfornis, Alfred, Consoli, Silla, Falissard, Bruno, Eymard, Elisabeth, Williams, Paul, Dejager, Sylvie
Publicado 2016

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

por Ahrén, Bo, Foley, James E., Ferrannini, Ele, Matthews, David R., Zinman, Bernard, Dejager, Sylvie, Fonseca, Vivian A.
Publicado 2010

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

por Ahrén, Bo, Foley, James Edward, Dejager, Sylvie, Akacha, Mouna, Shao, Qing, Heimann, Guenter, Dworak, Markus, Schweizer, Anja
Publicado 2014